Stocks and Investing Stocks and Investing
Tue, January 8, 2019
Mon, January 7, 2019
Fri, January 4, 2019
Thu, January 3, 2019
Wed, January 2, 2019
Mon, December 31, 2018
Fri, December 28, 2018
Thu, December 27, 2018
Wed, December 26, 2018
Fri, December 21, 2018
Thu, December 20, 2018
Wed, December 19, 2018

Matthew Harrison Maintained (UBX) at Buy with Decreased Target to $240 on, Dec 19th, 2018


Published on 2024-10-26 11:21:47 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Unity Biotechnology, Inc." (UBX) at Buy with Decreased Target from $250 to $240 on, Dec 19th, 2018.

Matthew has made no other calls on UBX in the last 4 months.



There is 1 other peer that has a rating on UBX. Out of the 1 peers that are also analyzing UBX, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Salim Syed of "Mizuho" Initiated at Strong Buy and Held Target at $330 on, Friday, September 7th, 2018